

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase, or subscribe for securities of the Company.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2496)

DELAY IN DESPATCH OF CIRCULAR IN RELATION TO

**(1) CONNECTED TRANSACTION IN RESPECT OF THE PROPOSED ISSUE OF
NEW DOMESTIC SHARES UNDER SPECIFIC MANDATE;**

(2) APPLICATION FOR WHITEWASH WAIVER; AND

(3) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Reference is made to the announcement of Wuhan YZY Biopharma Co., Ltd. (the “**Company**”) dated 9 September 2026 in relation to, among other things, the Share Subscription, the Specific Mandate, the Whitewash Waiver and the proposed amendments to the Articles (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those defined in the Announcement.

DELAY IN DESPATCH OF CIRCULAR

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among others, (i) details of the Share Subscription, the Specific Mandate, the Whitewash Waiver and the proposed amendments to the Articles; (ii) a letter of recommendation from the Connected Transaction IBC to the Independent Shareholders on the Share Subscription and the Specific Mandate; (iii) a letter of recommendation from the Whitewash Waiver IBC to the Independent Shareholders on the Share Subscription, the Specific Mandate and the Whitewash Waiver; (iv) a letter of advice by the Independent Financial Adviser to the Independent Board Committees and the Independent Shareholders on the Share Subscription, the Specific Mandate and the Whitewash Waiver; and (v) a notice of EGM together with the form of proxy, is expected to be despatched to Shareholders within 15 business days from the date of the Announcement pursuant to Rule 14A.68 of the Listing Rules or 21 days from the date of the Announcement pursuant to Rule 8.2 of the Takeovers Code, whichever is the earlier.

Considering additional time is required to prepare and finalise certain information to be included in the Circular, it is anticipated that the Circular may not be despatched around 30 September 2026. The Company has therefore applied to the Executive pursuant to Rule 8.2 of the Takeovers Code for the consent for an extension of time for the despatch of the Circular to a date falling on or before 30 October 2026. The Executive has indicated that it is minded to grant such consent.

Shareholders and potential investors of the Company should note that there is no assurance that the Share Subscription will proceed. The Company will publish announcement(s) to update the status of the Share Subscription as and when appropriate. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company and are recommended to consult their stockbroker, bank manager, solicitor or other professional adviser if they are in any doubt about their position and as to actions that they should take.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
Chairman of the Board,
Executive Director and Chief Executive Officer

Wuhan, PRC, 30 September 2026

As at the date of this announcement, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive Directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive Directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.

All the Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.